Which is the best combination therapy in relapsed and refractory multiple myeloma?
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Temsirolimus with BERT for the treatment of relapsed mantle cell and follicular lymphoma